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Introduction
Rheumatoid arthritis is a prototypical chronic inflam-
matory disease characterized by an imbalance of pro-
and anti-inflammatory mediators. Gene therapy has
been proposed as a means to restore impaired balance
by introducing anti-inflammatory genes into arthritic
joints (1). Studies in animal models have shown that
gene transfer technology is uniquely suited for thera-
peutic protein delivery in rheumatoid arthritis (2); two
phase I clinical trials in humans are currently underway
(3). A major challenge for the anti-inflammatory gene
therapy approach remains, however. Since rheumatoid
arthritis typically progresses through cycles of relapse
and remission, the production of a therapeutic protein
must be regulated in order to match the recurrent
course of the disease.
A number of vectors with drug-inducible promot-
ers for achieving regulatable transgene expression
have been described (4–8). In this approach, trans-
gene expression in vivo is regulated by an orally
bioavailable small-molecule drug. However, due to
the unpredictable course of the disease, this kind of
system will require long-term, largely empirical drug
adjustments made by the physician or the patient.
Overproduction of anti-inflammatory molecules
may be associated with tachyphylaxis, tissue toxicity,
or enhanced susceptibility to infection. In addition,
experimental evidence indicates that inappropriate
timing of anti-inflammatory protein administration
can undermine the efficacy of treatment (9). To avoid
these problems, we proposed an alternative approach
that we call physiologically responsive gene therapy
(PRGT) (10). In this approach, anti-inflammatory
transgene expression is autonomously regulated by
an inflammation-inducible promoter. In this study
we assessed the feasibility of using PRGT for treat-
ment of recurrent arthritis. In preliminary studies, we
developed a two-component expression system that
responds vigorously to inflammatory stimuli in vivo
(11). Here, we constructed an adenoviral vector car-
rying the cDNA of a pleiotropic anti-inflammatory
cytokine, human IL-10 (hIL-10), driven by the
inflammation-inducible promoter. We demonstrate
that intra-articular (IA) delivery of inflammation-
regulated hIL-10 effectively prevents recurrence of
streptococcal cell wall (SCW) arthritis in rats. The
recombinant therapeutic protein is produced in
direct relationship to the onset, severity, and dura-
tion of inflammation, thus indicating homeostatic
regulation of the therapeutic transgene.
Methods
SCW arthritis model. Female Lewis rats were obtained
from Charles River Laboratories (Wilmington, Massa-
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chusetts, USA) and used in the SCW reactivation
model of arthritis. In this model, an acute, transient,
monoarticular arthritis is produced by IA injection of
SCW fragments isolated from group A streptococci.
The primary structural components of the SCW frag-
ments are polymers of peptidoglycan-polysaccharide
(PG-APS). Several weeks after the IA injection, an intra-
venous injection of PG-APS induces reactivation of
chronic inflammatory arthritis in previously injured
joints (12). To assess joint inflammation, the lateral
diameters of ankle joints were measured in triplicate
using a digital caliper, as previously described (9, 13).
To reduce bias, all animals were coded and measure-
ments were done randomly.
For synovial lavages, ankles were excised and two
needles were inserted into the joint cavity. A 30-gauge
needle was used for the inflow of perfusion solution
(0.5 ml of PBS), and a 22-gauge needle was used for
collecting the perfusate. After centrifugation, super-
natants were frozen for subsequent quantification of
hIL-10. Sedimented cells were resuspended, red blood
cells were lysed, and white blood cells were counted
using a Coulter counter (Beckman Coulter Inc.,
Miami, Florida, USA).
To measure in vivo luciferase expression, excised
ankle joints were pulverized in liquid nitrogen and
extracted for 30 minutes on ice with 1 ml of an
extraction buffer (0.25 M Tris at pH 7.5, 10 mM
EDTA, 1 mM EGTA, 1 mM PMSF, 2.5 µg/ml apro-
tinin, 5 µg/ml leupeptin, and 2.5 µg/ml pepstatin).
Luciferase activity in the extracts was determined
using a luminometer. The possible influence of
quenchers or enhancers of luciferase activity in the
samples was controlled by determining chemilumi-
nescence of recombinant luciferase in the presence of
joint extracts.
Adenovirus preparation and storage. Adenoviruses (Ad)
were produced and purified as described (11). After
titration, each virus was frozen and stored at –70°C.
Immediately prior to IA injections, the viruses were
thawed and diluted in saline. In two in vivo experi-
ments and most of the in vitro studies, Ad viruses
were stored in 67 mM NaCl, 2.5 mM KCl, 0.5 mM
MgCl2, 10 mM Tris (pH 7.4), and 50% glycerol at
–20°C for up to 3 months. Unless otherwise noted, Ad
were injected intra-articularly at day –2, at 107 plaque-
forming units (PFU) per injection. When compared
with sham-injected joints, injection of reporter vec-
tors (Ad.C3-tat/HIV-luc and Ad.RR5) caused an
increase in joint diameter from day –2 to day 0 but did
not influence the severity of recurrence induced by
PG-APS injection at day 0.
Cell culture. Primary rat synovial fibroblasts were
obtained by enzymatic dispersal of synovial explants
from rats with SCW arthritis (13). Cells were maintained
in RPMI 1640 with 15% FBS and used at passages 5–10.
Immunodetection methods. Cell lysates were resolved on
a denaturing 15% SDS-polyacrylamide gel and trans-
ferred to nitrocellulose. hIL-10 was detected with a
polyclonal primary hIL-10 antibody sc-1273 (1:1,000)
(Santa Cruz Biotechnology Inc., Santa Cruz, California,
USA). Immune complexes were visualized using sec-
ondary horseradish peroxidase–conjugated antibody
(1:3,000) and a Renaissance ECL kit (NEN Life Science
Products Inc., Boston, Massachusetts, USA). To assess
hIL-10 in vivo, synovial lavages were pooled (four joints
at each time point), forty microliters of the mixture
were resolved on SDS-polyacrylamide gel and immuno-
detected with hIL-10 antibody, as above. Human
recombinant IL-10 (Biosource International, Camaril-
lo, California, USA) provided a positive control. hIL-10
ELISA was performed on coded samples using anti-
bodies and recombinant hIL-10 from Pharmingen (San
Diego, California, USA).
Results
The two-component C3-tat/HIV promoter is a broadly respon-
sive sensor of chronic inflammation. In order to achieve
physiological regulation of anti-inflammatory trans-
genes, a promoter element should satisfy certain crite-
ria. First, it should respond to the principal proin-
flammatory mediators. Second, to provide a large
dynamic range of responses, it should have low-level
basal activity and high inducibility. Finally, the fully
activated promoter should be able to drive the produc-
tion of sufficient amounts of recombinant protein to
achieve a therapeutic effect. Transcription of many
acute-phase protein (APP) genes is controlled by
inflammation-inducible promoters, which respond to
inflammatory stimuli in a dose-dependent fashion.
However, the absolute levels of expression achievable by
vectors with endogenous APP gene promoters are dis-
appointingly low compared with levels provided by the
strong constitutive cytomegalovirus (CMV) promoter
(14). In our previous studies, we developed a two-com-
ponent inflammation-inducible expression system.
This chimeric construct uses the promoter of the com-
plement factor 3 (C3) APP gene to control the expres-
sion of the HIV Tat protein; in the same construct, Tat
transactivates the expression of a transgene (rX) linked
to the HIV promoter (11) (Figure 1). Since both the C3
and HIV promoters are cytokine responsive, this bina-
ry construct allows both cis and trans activation of rX
production by inflammatory mediators. When this
binary element was incorporated into a nonreplicating
Ad and injected into mice, it exhibited high inducibili-
ty in several tissues in response to bacterial endotoxin
and turpentine oil, and after induction it attained lev-
els of rX expression comparable to those provided by
the CMV promoter (11).
Here we first examined the ability of the C3-tat/HIV
promoter to respond in vitro to important mediators
of chronic inflammation. Primary synovial fibroblasts
derived from arthritic rat joints were infected with a
reporter Ad (Ad.C3-tat/HIV-luc). Control cells were
infected with the empty vector (Ad.RR5) or with an Ad
that produces luciferase under the control of the CMV
promoter (Ad.CMV-luc). Following adenoviral infec-
1224 The Journal of Clinical Investigation | May 2002 | Volume 109 | Number 9
tion, serum-starved cells were stimulated with LPS (10
µg/ml), IL-1, IL-6, or TNF-α (each cytokine was used
at a concentration of 20 ng/ml). The stimuli activated
C3-tat/HIV promoter by approximately four to five
orders of magnitude, and the peak levels were compa-
rable to those provided by the CMV promoter (Figure
2, a and b). Of note, CMV-driven luciferase expression
was also activated by these stimuli, although the range
of induction (approximately twofold) was far less than
was seen with the C3-tat/HIV promoter. As IL-1, IL-6,
and TNF-α are considered the pivotal cytokines in
chronic inflammation, the C3-tat/HIV element thus
appears to be a broadly responsive “sensor” of inflam-
mation with a very large dynamic range.
Recurrence of SCW arthritis induces activation of C3-tat/
HIV promoter in vivo. To assess the inducibility of the
C3-tat/HIV promoter by chronic inflammation in
joints in vivo, we first examined the expression of the
luciferase reporter during the reactivation phase of
SCW arthritis in rats. A distinct feature of this model is
the predictability of the recurrence, which reaches a
peak at 2 to 4 days and gradually subsides thereafter
(12). Ad.C3-tat/HIV-luc and control Ad vectors were
injected into primed ankle joints 2 days prior to reacti-
vation of SCW arthritis. In the absence of reactivation,
the luciferase activity in the joints injected with Ad.C3-
tat/HIV-luc was low, but following reactivation, it
achieved the levels attainable with the constitutive
CMV promoter (Figure 2c). In three independent exper-
iments, luciferase activity peaked at 2 to 4 days after
reactivation; the maximal induction was in the range of
18- to 80-fold compared with unreactivated joints.
Inflammation-inducible production of hIL-10 in vitro.
When considering the candidacy of a transgene for a
therapeutic protocol, we reasoned that the transgene
product should inhibit the numerous inflammatory
pathways acting upon the inducible promoter; other-
wise, the inducible promoter might remain activated
by unchecked proinflammatory mediators. In previous
studies we determined that simultaneous suppression
of many inflammatory responses, including the induc-
tion of IL-1, IL-6, and TNF-α, can be achieved by block-
ing activation of the transcription factor NF-κB (15,
16). Anti-inflammatory cytokine IL-10 is a potent
extracellular antagonist of NF-κB activation (17, 18);
in addition, several recent reports have demonstrated
the therapeutic efficacy of unregulated IL-10 gene
transfer in animal models of rheumatoid arthritis
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Figure 1
The two-component C3-tat/HIV promoter. LTR, long terminal repeat.
Figure 2
The two-component C3-tat/HIV promoter is a broadly responsive
sensor of chronic inflammation. (a and b) Induction by the principal
proinflammatory cytokines in vitro. Primary synovial fibroblasts were
infected in vitro by incubating overnight with the indicated Ad vec-
tors at a multiplicity of infection of 100. Twenty-four hours later, cells
were starved in 0.5% FBS medium for 24–48 hours, followed by stim-
ulation for 6 hours with the indicated cytokines (20 ng/ml) or LPS
(10 µg/ml). Luciferase activity in cell lysates was normalized to total
protein. (a) The levels of inflammation-inducible C3-tat/HIV–driven
expression are comparable to those attainable with the CMV pro-
moter. Data are presented as mean of duplicate measurements with-
in an individual experiment; error bars show SD. (b) The C3-tat/HIV
promoter provides a large dynamic range of response. The values of
fold induction were calculated as the average of readings in inde-
pendent experiments performed in duplicate (two experiments with
IL-1 and IL-6 and three experiments with TNF-α and LPS). (c) In vivo
induction following reactivation of SCW arthritis. On day –42, ani-
mals were primed by IA injection of PG-APS in both ankle joints. The
same joints were injected with the indicated Ad vectors (107 PFU in
10 µl) on day –2. On day 0, arthritis was reactivated by an intra-
venous injection of PG-APS. Luciferase activity was measured in
extracts of pulverized joints (each bar shows the mean ± SD of two
joints). In three independent experiments, luciferase activity peaked
on day 2–4 and remained elevated through day 4. Unstim., unstim-
ulated; IV, intravenous; rlu, relative luciferase units.
(19–23). We therefore constructed an adenoviral vector
(Ad.C3-tat/HIV–hIL-10) expressing the cDNA of 
hIL-10. Control viruses were Ad.C3-tat/HIV-luc, the
empty vector Ad.RR5, and Ad.CMV–hIL-10, an Ad that
produces hIL-10 constitutively under the control of
the CMV promoter. Synovial cells infected in vitro with
Ad.C3-tat/HIV–hIL-10 produced undetectable
amounts of hIL-10, whereas treatment with TNF-α or
LPS resulted in secretion of hIL-10 in concentrations
similar to those produced by cells infected with
Ad.CMV–hIL-10 (Figure 3a). The secreted hIL-10 was
biologically active: it effectively antagonized induction
of NF-κB DNA-binding activity in primary synovio-
cytes in response to TNF-α (Figure 3b), prevented acti-
vation of NF-κB reporter gene expression in TNF-α–
and LPS-stimulated L929 fibroblasts (not shown), and
suppressed IL-6 production by LPS-stimulated murine
macrophages (not shown).
Gene transfer of inflammation-inducible hIL-10 prevents
reactivation of SCW arthritis. To assess the therapeutic
efficacy of inflammation-inducible hIL-10 expression,
PG-APS–primed rat ankle joints were injected with
Ad.C3-tat/HIV–hIL-10 or control vectors 1–2 days
before arthritis was reactivated by an intravenous injec-
tion of PG-APS. The severity of inflammation after
reactivation was assessed by measuring joint swelling
(13, 16) and the numbers of leukocytes within the
joints (24). As determined in two independent experi-
ments, gene transfer of inflammation-inducible hIL-10
afforded efficacious protection against reactivation-
induced leukocytosis (Figure 4a and data not shown).
Inflammation-inducible hIL-10 gene transfer also sig-
nificantly inhibited joint swelling (Figure 4b). Inhibi-
tion of joint swelling by Ad.C3-tat/HIV–hIL-10 gene
transfer was statistically significant in four independ-
ent experiments (Table 1). In one experiment, Ad.C3-
tat/HIV–hIL-10 gene transfer did not result in statisti-
cally significant suppression of joint swelling (P > 0.05).
Homeostatic regulation of inflammation-inducible hIL-10
expression in vivo. Quantitative assessments of hIL-10 in
joint lavages by ELISA showed that, in the absence of
reactivation, hIL-10 levels in joints injected with Ad.C3-
tat/HIV–hIL-10 were at the lower limit of detection (1
ng/ml). Reactivation of arthritis caused striking increas-
es in hIL-10 levels on days 1 and 2, returning to near-
baseline (unreactivated) levels on day 4 (Figure 5a).
Since ELISA readings can be influenced by various
inhibitors often found in biological fluids, we addi-
tionally examined hIL-10 expression using Western
blotting. As shown in Figure 5b, qualitative assessments
based on Western blotting were in good agreement with
the ELISA readings. In contrast to the joints injected
with Ad.C3-tat/HIV–hIL-10, hIL-10 production from
Ad.CMV–hIL-10 persisted at a constant level through-
out the observation period (Figure 5b). The observed
sustained expression of Ad.CMV–hIL-10 is consistent
with our previous observation that the expression of a
CMV-driven reporter green fluorescence protein per-
sisted for at least 1 week after Ad gene transfer into
arthritic rat joints (16). This refutes the possibility that
the shutoff of inflammation-inducible hIL-10 expres-
sion at day 4 was a consequence of an immune response
directed against Ad-transduced cells. Another possible
explanation is that suppression of the antiapoptotic
NF-κΒ pathway (16) by IL-10 might lead to elimination
of Ad-infected cells; however, persistence of CMV-driv-
en hIL-10 expression (Figure 5b) argues against this
possibility. Furthermore, inflammation-inducible
luciferase expression persisted through day 4 (Figure
2c), strongly suggesting that the rapid decline of Ad.C3-
tat/HIV–hIL-10 expression was a direct consequence of
hIL-10–mediated inhibition of inflammation, with sub-
sequent downregulation of the inflammation-inducible
promoter. We therefore conclude that gene transfer
mediated by Ad.C3-tat/HIV–hIL-10 establishes a nega-
tive feedback loop similar to those involved in homeo-
static regulation of endogenous inflammatory genes.
The severity of recurrent SCW arthritis in rats can be
regulated by varying the doses of intra-articularly and
intravenously injected PG-APS and the interval
between priming and reactivation (12). This allowed
us to investigate the relationship between the severity
of recurrent arthritis and IA production of inflamma-
tion-inducible hIL-10. In three independent experi-
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Figure 3
(a) Inflammation-inducible production of hIL-10 in primary synovial
fibroblasts in vitro. Cells were infected as for Figure 2a and stimulat-
ed with LPS (1 µg/ml) or TNF-α (10 ng/ml) for 48 hours. The levels
of hIL-10 in conditioned media were assessed by Western blotting.
The hIL-10 band was identified by comparison with a recombinant
hIL-10 standard (not shown). Data representative of two independ-
ent experiments are shown. (b) Adenoviral hIL-10 inhibits NF-κB acti-
vation in vitro. Conditioned medium from TNF-α–stimulated infect-
ed cells (shown in a, lanes 3, 6, and 9) was added to uninfected
primary synovial fibroblasts; where indicated, recombinant hIL-10
(rhIL-10; 100 ng/ml) was also added. After 10 minutes of preincu-
bation, TNF-α (100 ng/ml) was added for a 15-minute incubation
period. NF-κB DNA-binding activity in nuclear extracts was analyzed
by electromobility shift assay (EMSA). NS, nonspecific bands.
ments, IA hIL-10 levels in joints injected with Ad.C3-
tat/HIV–hIL-10 increased 16-, 70-, and 288–fold above
baseline by day 2–4 (Table 1). The maximal fold induc-
tion in hIL-10 concentration was directly related to the
severity of SCW arthritis in the corresponding control
groups (r = 0.93) (Figure 5c). In those experiments, IA
hIL-10 levels returned to near baseline by day 4. These
data suggest strongly that inflammation-inducible
expression of hIL-10 occurred in direct relationship to
the intensity and duration of inflammation.
Discussion
The objective of our work was to test the concept of
PRGT for treating a recurrence of chronic inflamma-
tion. The benefits of the approach seem self-evident,
but the feasibility of self-regulated anti-inflammatory
gene therapy is yet to be established. Numerous trans-
genes have been shown to prevent experimental arthri-
tis, including IL-10 (19–23), soluble TNF receptors, 
IL-1 receptor antagonist, Fas ligand, and TGF-β (13,
25–29), and several inflammation-inducible promoters
have been described (10, 14, 30, 31). However, it was not
at all clear whether an autoregulated system would
work to prevent inflammation in vivo. The fact that
our two-component inflammation-inducible construct
responded to a high concentration of systemic inflam-
matory stimuli (e.g., LPS and turpentine) was encour-
aging, but this did not guarantee that the promoter
would similarly respond to the recurrence of chronic
inflammation, or that this would work in the context
of the synovium. It was also not at all clear whether the
promoter could induce the expression of tangible
amounts of therapeutic proteins. We also did not know
if the inducible IL-10 production would be beneficial,
because inappropriate timing can diminish the effica-
cy of anti-inflammatory proteins (9).
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Figure 4
Gene transfer of inflammation-inducible hIL-10 prevents reactiva-
tion of SCW arthritis. (a) Inhibition of leukocytosis. On day –42,
animals were IA injected with PG-APS in both ankle joints. On day
–1, animals were injected in both ankle joints with the indicated Ad,
as for Figure 2b. In this experiment there were 12 animals per group
on day –1. On day 0, reactivation was induced by intravenous injec-
tion of PG-APS. On days 0, 1, 2, 3, 4, and 6 after reactivation, two
animals from each group were euthanized, and ankle joints were
perfused for determining the numbers of infiltrating white blood
cells (WBCs) (21). The time course of leukocytosis is shown. Each
bar shows the mean ± SEM of measurements from four joints. Data
representative of two experiments are shown. (b) Inhibition of joint
swelling. In parallel to measuring leukocytosis, inflammation was
assessed by measuring joint swelling. As animals in each group were
euthanized in order to obtain joint lavages, the data points repre-
sent a diminishing number of joints. Swelling was calculated as 
(di) – (d0), where (di) and (d0) are mean joint diameters at day i and
day 0. Error bars represent SEM. P values for comparisons between
groups in a and b were calculated using the unpaired one-tailed Stu-
dent t test. Data on inhibition of joint swelling in other experiments
are presented in Table 1.
Table 1
Therapeutic efficacy of inflammation-inducible hIL-10 gene transfer in SCW arthritis
Experiment Ad vector AMax. swelling (mm) ± SEM BInhibition of swelling (%) C(P value) DMax. hIL-10 induction (fold)
1 None 1.13 ± 0.25 (n = 10)
Ad.C3-tat/HIV-luc 1.28 ± 0.16 (n = 10)
Ad.C3-tat/HIV–hIL-10 0.53 ± 0.21 (n = 12) E59% (P < 0.01) ND
2 Ad.C3-tat/HIV-luc 1.61 ± 0.17 (n = 4)
Ad.C3-tat/HIV–hIL-10 0.76 ± 0.29 (n = 4) 53% (P < 0.05) 288
3 Ad.RR5 0.91 ± 0.15 (n = 12)
Ad.C3-tat/HIV–hIL-10 –0.25 ± 0.07 (n = 12) 100% (P < 0.005) 16
4 Ad.C3-tat/HIV-luc 0.75 ± 0.05 (n = 12)
Ad.C3-tat/HIV–hIL-10 0.43 ± 0.04 (n = 12) 43% (P < 0.005) 70
ACalculated as joint swelling in relation to day 0: ∆ = (dmax) – (d0), where (dmax) is the maximal joint diameter throughout the observation period, and (d0) is joint diam-
eter at day 0 (average of n joints). BCalculated as (∆control group – ∆experimental group)/∆control group) × 100%. CThe significance of difference in reactivation-induced joint swelling
between groups was calculated using the unpaired one-tailed Student t test. DMean values of IA hIL-10 were calculated as the average of four joints per group. Max-
imal values of hIL-10 induction throughout the observation period are shown. ECompared with Ad.C3-tat/HIV-luc group. Max., maximal. ND, not determined.
In this context, the novelty and the significance of our
work is the demonstration that autoregulatory gene
therapy for rheumatoid arthritis is feasible. A distinct
advantage of this strategy is that it inhibits inflamma-
tion while carrying minimal risk of tissue toxicity or
tachyphylaxis from persistent overproduction of the
transgene product(s). In this method, compared with
other methods for anti-inflammatory drug administra-
tion, the risk of unwanted immunosuppression can also
be reduced: the drug may be made when, where, in the
necessary amount, and for only as long as is necessary
for the control of local inflammation.
Our study represents proof of principle rather than a
description of a construct immediately available for
clinical use. The most serious practical issue remains the
selection of a vector for inflammation-inducible gene
delivery. Ad vectors are known to induce inflammation
within the joint approximately 2 weeks after Ad infec-
tion. This limitation precluded examination of the
long-term effects of inflammation-inducible expression
in the present study. In this regard, use of low-immuno-
genic vectors such as adeno-associated virus–based vec-
tors (32) may be advantageous, especially because
adeno-associated virus–based vector expression is
reportedly elevated in the inflamed joints (33–35).
Another concern was that the expression of Tat in our
promoter might cause unwanted effects, e.g., cytotoxic-
ity, immunogenicity, and inflammation. We investigat-
ed this in several experiments. In one set of experiments,
we compared swelling induced in PG-APS–primed
joints by Ad.C3-tat/HIV-luc with that produced by
empty Ad.RR5 and Ad.CMV vectors; we found no sig-
nificant difference (data not shown). In another set of
experiments, having compared the severity of PG-APS–
induced arthritis recurrence in joints injected with
Ad.C3-tat/HIV-luc, Ad.RR5, and saline, we also did not
observe significant differences (data not shown). A high-
titer (100 PFU/cell) infection of synovial cells in vitro
with Ad vectors containing C3-tat/HIV promoter did
not cause cytotoxicity (data not shown). As we used low
titers in vivo (107 PFU/joint, which in our estimation
corresponded to less than 1 PFU/cell in vivo), this
makes cytotoxic effects of C3-tat/HIV in vivo unlikely.
These observations argue against the cytotoxic and
proinflammatory effects of Tat in our experiments. One
possible explanation is that many effects of Tat have
been attributed to the second exon of tat, which is not
present in our construct. Another possibility is that, in
the two-component C3-tat/HIV construct, Tat expres-
sion is driven by a weak C3 promoter. As we showed pre-
viously, even a fully induced C3 promoter provides
expression that is two to three orders of magnitude
lower than that achieved with strong viral promoters
(11, 14); therefore the amount of Tat protein should be
much less than that described in most experiments
using constitutively overexpressed Tat.
In conclusion, our data indicate that the physio-
logically regulated transgene supplements an inade-
quate endogenous anti-inflammatory response, thus 
becoming an integral part of the negative physiological
feedback to inflammation. Potential clinical targets for
endogenously regulated gene therapy are not limited to
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Figure 5
The expression of inducible hIL-10 transgene in vivo. (a) Reactivated vs.
unreactivated joints. Animals with PG-APS–preinjured ankle joints
received IA Ad.C3-tat/HIV–hIL-10 on day –2. Arthritis was reactivated
in half the animals by intravenous PG-APS (black bars) on day 0. The
other half was sham-injected with saline (white bars). The concentra-
tions of hIL-10 in joint perfusates were assessed by ELISA. Each bar
shows the mean ± SEM of four joints. In the unreactivated group, 
hIL-10 concentrations were at or below the limit of detection (1 ng/ml).
In a control group (Ad.C3-tat/HIV-luc injected animals), the expression
of luciferase has reached a peak at day 4 after reactivation (data not
shown). (b) Constitutive vs. inducible transgene expression. In a simi-
lar experiment, animals were IA injected at day –2 with the constitutive
Ad.CMV-hIL-10 or inducible Ad.C3-tat/HIV–hIL-10. Following reacti-
vation of arthritis (day 0), hIL-10 levels in joint lavages were assessed by
Western blotting. Ad.RR5: perfusates of joints injected with an empty
Ad. Each lane represents a pool of four joints. In a parallel control exper-
iment, animals were IA injected with Ad.C3-tat/HIV-luc reporter, which
expression persisted through day 4 (data represented by Figure 2c). (c)
Levels of inflammation-induced hIL-10 correlate with the severity of
arthritis. Each point represents data from an independent experiment
and is the average of four or more joints (see Table 1); error bars equal
± SEM. Abscissa: maximal SCW-induced swelling in the counterpart
control animals (injected with empty or with reporter Ad). Ordinate:
maximal average hIL-10 induction [hIL-10 (reactivated joints)/hIL-10
(unreactivated joints)] in Ad.C3-tat/HIV–hIL-10 injected animals.
rheumatoid arthritis; they include a variety of chronic
inflammatory diseases, such as Crohn disease and
organ transplant rejection (10). It should be possible to
regulate the production of many different proteins in
this way, using vectors and inflammation-inducible
promoters that, like the therapeutic transgene, are tai-
lored to specific clinical settings. The principle of
endogenously regulated gene therapy for treating
inflammation should therefore not be limited to the
promoter system and transgene studied here.
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